Viewing StudyNCT05837052



Ignite Creation Date: 2024-05-06 @ 6:56 PM
Last Modification Date: 2024-10-26 @ 2:57 PM
Study NCT ID: NCT05837052
Status: RECRUITING
Last Update Posted: 2023-07-17
First Post: 2023-04-17

Brief Title: A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Sponsor: Zhejiang University
Organization: Zhejiang University

Conditions & Keywords Data

Conditions:
Name
Unresectable Lung Non-Small Cell Carcinoma
Keywords:
Name View
Conversion treatment View
Unresectable NSCLC View
Serplulimab View